NeuroOne® to Present Its Breakthrough Technology for Monitoring Neural Activity at the H.C. Wainwright Global Investment Conference on May 25
NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) will present its innovative technology at the H.C. Wainwright Global Investment Conference from May 23-26, 2022 in Miami. The presentation is scheduled for May 25, 2022, at 3:30 PM ET, and will be available via webcast. CEO Dave Rosa will highlight progress in minimally invasive, high-precision solutions for neurological conditions. NeuroOne aims to reduce costs and improve patient outcomes using advanced electrode technologies. For more information, visit n1mtc.com.
- None.
- None.
EDEN PRAIRIE, Minn., May 19, 2022 /PRNewswire/ -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announced that it will present at the H.C. Wainwright Global Investment Conference being held May 23-26, 2022 virtually and in Miami, Florida. NeuroOne will present Wednesday, May 25, 2022, from 3:30 PM - 4:00 PM ET, and the presentation will be available on-demand via webcast.
Details of NeuroOne's presentation are as follows:
H.C. Wainwright Global Investment Conference | |
Presentation date and time: | Wednesday, May 25, 2022; 3:30 p.m. ET |
Location: | Online and at the Fontainebleau Miami Beach Hotel, Miami Beach, Florida |
Registration: | Visit the conference website to register for either in-person or virtual attendance |
Webcast: | Available here at the time of presentation |
Webcast Replay: | Available for 90 days |
NeuroOne Chief Executive Officer Dave Rosa will discuss the Company's progress in developing and commercializing minimally invasive and high-definition/high-precision solutions for neurologic conditions such as epilepsy, Parkinson's disease, dystonia, and essential tremors, as well as chronic pain from failed back surgeries. These solutions include minimally invasive thin-film Evo® Cortical Electrodes that have the potential to reduce costs, hospitalizations, and surgical procedures and improve patient outcomes.
About NeuroOne® Medical Technologies Corporation
NeuroOne is a medical technology company focused on the development and commercialization of minimally invasive and high-definition/high-precision solutions for epilepsy, Parkinson's disease, dystonia, essential tremors, and chronic pain due to failed back surgeries. A combination recording and RF ablation technology is currently under development. In addition, NeuroOne is currently testing its electrodes for long term stimulation. The Company is also investigating the potential application of its technology for artificial intelligence and machine learning. Visit n1mtc.com.
Forward Looking Statements
This press release may include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Except for statements of historical fact, any information contained in this presentation may be a forward–looking statement that reflects the Company's current views about future events and are subject to known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. In some cases, you can identify forward–looking statements by the words or phrases "may," "might," "will," "could," "would," "should," "expect," "intend," "plan," "objective," "anticipate," "believe," "estimate," "predict," "project," "potential," "target," "seek," "contemplate," "continue, "focused on," "committed to" and "ongoing," or the negative of these terms, or other comparable terminology intended to identify statements about the future. Forward–looking statements may include statements regarding potential of our technology to reduce the number of hospitalizations, surgical procedures and reduce costs. Although the Company believes that we have a reasonable basis for each forward-looking statement, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations of the future, about which we cannot be certain. Our actual future results may be materially different from what we expect due to factors largely outside our control, including risks that our technology will not perform as expected based on results of our pre-clinical testing; uncertainties inherent in the development process of our technology; risks related to changes in regulatory requirements or decisions of regulatory authorities; risks that we may not have accurately estimated the size and growth potential of the markets for our technology; and other risks and uncertainties related to market and other conditions, the impact of general economic, industry or political conditions in the United States or internationally and those described under the heading "Risk Factors" in our filings with the Securities and Exchange Commission. These forward–looking statements speak only as of the date of the press release and the Company undertakes no obligation to revise or update any forward–looking statements for any reason, even if new information becomes available in the future.
View original content to download multimedia:https://www.prnewswire.com/news-releases/neuroone-to-present-its-breakthrough-technology-for-monitoring-neural-activity-at-the-hc-wainwright-global-investment-conference-on-may-25-301551007.html
SOURCE NeuroOne Medical Technologies Corporation
FAQ
When will NeuroOne present at the H.C. Wainwright Global Investment Conference?
Where is the H.C. Wainwright Global Investment Conference taking place?
What technology will NeuroOne present at the conference?
How can I view the NeuroOne presentation?
What is NeuroOne's focus in medical technology?
